---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-147538"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T21:11:29.426366+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cytek Q1 revenue up 44% to $35.1M; raises FY2022 revenue guidance

## Summary
- Revenue $35.1M, +44% YoY; installed base grew to 1,226 instruments with 116 new placements.
- GAAP net loss of $2.2M vs net income of $0.1M last year; operating loss $2.4M vs income $1.1M.
- Adjusted EBITDA $1.9M, up from $1.1M; adjusted gross margin 61% vs 60%.
- FY2022 revenue guidance raised to high end of $160M-$168M range.
- Service revenue more than doubled from prior year.

## SEC filing metadata
- accession: 0001193125-22-147538
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312522147538/0001193125-22-147538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312522147538/d315155d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-147538
- JSON: https://secwatch.observer/filing/0001193125-22-147538.json
- Plain text: https://secwatch.observer/filing/0001193125-22-147538.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.